Vital Therapies, Inc. is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure. Its product candidate include the ELAD System (ELAD), is a Phase 3 investigational extracorporeal bio-artificial liver therapy designed to supplement hepatic function in order to improve survival rates among patients with acute liver failure. ELAD consists of a reusable bedside unit attached to four disposable cartridges, which collectively contain thousands of hollow fibers and approximately one pound of immortal human C3A cells from its cell bank. The Company is conducting three Phase III clinical trials in various forms of acute liver failure.